1. Home
  2. MAX vs MLYS Comparison

MAX vs MLYS Comparison

Compare MAX & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MediaAlpha Inc.

MAX

MediaAlpha Inc.

HOLD

Current Price

$9.53

Market Cap

722.8M

Sector

Industrials

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$23.51

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MAX
MLYS
Founded
2014
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
722.8M
2.4B
IPO Year
2020
2023

Fundamental Metrics

Financial Performance
Metric
MAX
MLYS
Price
$9.53
$23.51
Analyst Decision
Buy
Strong Buy
Analyst Count
6
6
Target Price
$14.58
$48.67
AVG Volume (30 Days)
966.3K
1.1M
Earning Date
04-29-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
25.81
37.43
EPS
0.39
N/A
Revenue
$1,113,600,000.00
N/A
Revenue This Year
$12.70
N/A
Revenue Next Year
$9.32
N/A
P/E Ratio
$24.95
N/A
Revenue Growth
28.78
N/A
52 Week Low
$7.09
$10.44
52 Week High
$13.92
$47.65

Technical Indicators

Market Signals
Indicator
MAX
MLYS
Relative Strength Index (RSI) 48.94 30.24
Support Level $9.45 $13.42
Resistance Level $10.93 $31.09
Average True Range (ATR) 0.41 1.76
MACD 0.01 -0.30
Stochastic Oscillator 16.17 11.34

Price Performance

Historical Comparison
MAX
MLYS

About MAX MediaAlpha Inc.

MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: